Integrating Nanotechnology and Mitochondrial Targeting in the Treatment of Cancer

Rahul Chatterjee[1], Madhurima Basak[1], Sriparna De[1], Abhishek Jana[1],Dipanjan Bhattacharjee[1*]

[1]Department of Allied Health Sciences, Barasat, Kolkata, West Bengal 700125

Abstract

Mitochondria play a pivotal role in the regulation of cellular metabolism and apoptosis; thus, they are key targets for inducing selective cell death in cancer cells. With the help of nanotechnology, therapeutic agents can be delivered to mitochondria precisely, with increased targeting specificity, reduced systemic toxicity, and successful circumvention of multidrug resistance, which is a significant barrier to traditional cancer therapy.

The therapeutic efficacy of these integrated approaches is also explained by the preclinical studies conducted to date (for a wide range of different cancer types). Such studies have shown an increase in anticancer action, an increase in drug bioavailability, and a decrease in off-target effects compared to conventional treatment. Critical issues that inhibit clinical translation are also discussed in this chapter and include the stability of nanoparticles in biological environments, accuracy in targeting, possibility of immunogenicity, and biocompatibility issues.

Solutions that are emerging, such as surface modification with targeting ligands, release systems that respond to stimuli, and multifunctional nanocarriers, are being discussed as alternative solutions to address these shortcomings. Finally, the chapter provides future directions that focus on the avenues of multidisciplinary endeavours to waste more nanocarrier engineering, higher targeting precision, and easier regulatory development. This holistic summary provides the scientists and clinicians with a powerful framework to unlock the synergistic capabilities of nanotechnology and mitochondrial targeting and eventually help to evolve more effective, individualized and safer cancer treatments.

Keywords: Nanotechnology, Mitochondrial targeting, Mitochondria, Nanocarriers, Liposomes

1. Introduction:

(a). Background on cancer and current treatment challenges

Cancer represents a leading global health crisis characterized by uncontrolled proliferation and metastatic potential, causing substantial mortality and socioeconomic burden. Its heterogeneity complicates effective intervention. Conventional modalities—surgery, chemotherapy, radiotherapy—remains foundational yet limited: surgery fails metastatic disease; chemotherapy lacks specificity causing systemic toxicity, radiotherapy damages adjacent tissues, and resistance drives recurrence. Targeted, personalized approaches are urgently needed.[1]

Molecular biology advances identify oncogenic drivers, enabling selective pathway inhibitors that spare normal cells. Precision medicine tailors regimens to patient profiles, optimizing efficacy while minimizing toxicity—a paradigm shift toward sustainable cancer management.[2]

(b). Introduction to nanotechnology in cancer treatment

Nanotechnology manipulates materials at 1-100 nm scales, yielding unique physicochemical properties for molecular interventions. Nanoparticles penetrate biological barriers and accumulate preferentially in tumors via enhanced permeability retention (EPR) effects, reducing systemic exposure while concentrating payloads. Multifunctional designs integrate targeting ligands, imaging agents, and therapeutics. Tunable properties enhance stability, circulation, and immune evasion.Applications encompass carrier systems (liposomes, polymers, dendrimers, metals) delivering chemotherapeutics, genes, and immunotherapies; controlled/stimuli-responsive release; enhanced imaging for early detection and therapy monitoring. These innovations address conventional limitations, advancing personalized oncology.[3]

(c). Mitochondria as therapeutic targets in cancer

Mitochondria are important regulators of cell fate, as they are central to cellular metabolism and apoptosis. They are the most important source of ATP via oxidative phosphorylation, providing the energy required to power numerous cellular processes. In addition to energy production, mitochondria program cell death (apoptosis) through the release of pro-apoptotic substances, such as cytochrome c, which activates caspase proteins that cause cell death in a controlled manner. This dual role in energy generation and apoptosis makes mitochondria important components of cellular homeostasis. In most cases, mitochondrial function in cancer cells is confused to enhance unregulated growth and survival. These changes involve metabolic reprogramming, in which cancer cells

convert glycolysis (the Warburg effect) under aerobic conditions, despite the use of oxidative phosphorylation, which enhances quick energy generation and biosynthesis.[4]

Mutations in mitochondrial DNA, alterations in mitochondrial membrane potential, and apoptotic pathway dysregulation also play a role in cancer progression and resistance to cell death. This type of mitochondrial dysfunction facilitates tumour development, spread, and resistance to traditional treatments. Mitochondria-targeted therapy of cancer could be one of the alternatives because mitochondria play a central role in the metabolism and survival of tumour cells. Therapeutic strategies are designed to disrupt mitochondrial bioenergetics, induce mitochondrial-mediated apoptosis, or reverse metabolic changes specific to cancer cells. By selectively targeting mitochondrial functioning and killing tumour cells while avoiding normal cells, resistance to conventional therapies can be overcome, and potentially overcome the resistance to these strategies. Furthermore, other treatment techniques can be applied in combination with mitochondria-targeted agents to achieve greater efficacy and reduce systemic toxicity, thereby promoting personalised and targeted cancer treatment.[5, 6]

2. Design and Development of Mitochondrial-Targeted Nanocarriers

(a). Types of nanocarriers for mitochondrial targeting

Liposomes: Liposomes consist of spherical vesicles comprising one or more phospholipid bilayers filled with an aqueous core. They are amphiphilic, meaning that they carry both hydrophilic and hydrophobic drugs, and can be highly diversified in the choice of delivery vehicles. Liposomes are biocompatible and biodegradable, rendering them less toxic and increasing their circulation time in the body. Their shape facilitates fusion with cellular membranes, and fusion assists in the efficient delivery of cellulites. Liposomes can be functionalized with ligands or peptide functional groups that target them to mitochondria to enhance drug selectivity and therapy.[7]

Polymeric nanoparticles: Polymeric nanoparticles are hard colloidal particles comprising biodegradable and biocompatible polymers, such as PLGA, PEG, or chitosan. They are versatile in terms of drug loading, release kinetics, and surface modification. The tunable characteristics of size and surface allow them to circulate for extended periods and exhibit enhanced cellular uptake. In the case of mitochondrial targeting, the polymeric nanoparticles can also be designed and modified to contain mitochondrial-targeting ligands or stimuli-responsive functional groups

that will precipitate drug release within the mitochondrial environment. This versatility makes them attractive platforms for the direct administration of therapeutic agents to mitochondria and enhancement of treatment outcomes, while limiting systemic toxicity.[8, 9]

(b). Physicochemical properties for efficient mitochondrial delivery

Physicochemical properties have a strong influence on the effectiveness of mitochondrial delivery of nanocarriers, including cellular uptake, intracellular transport, and mitochondrial targeting. Cellular uptake size and shape. The size of nanocarriers is essential for targeting cells and mitochondria.

Nanoparticles with diameters of 20–200 nm are best suited to be delivered to cells, as endocytosis and clearance occur at distinct times, which makes uptake effective and clearance slow. Smaller particles can more easily enter cellular membranes and are directed into intracellular compartments to reach the mitochondria. The form also plays a role in uptake; the uptake of cellular tissue is usually stronger in the case of spherical nanoparticles than in the case of rod- or disk-shaped particles, as spherical particles are more likely to interact with the cell membrane and are also easier to endocytose. Nonetheless, long or curved forms can assist in intracellular movements and mitochondrial targeting by assisting membrane fusion or intrusion. Influence of surface charge on mitochondrial targeting. Surface charge has a major influence on cellular uptake and targeting in the mitochondrion. Positively charged nanocarriers have more spatial interactions with the negatively charged cell and mitochondrial membranes, leading to better internalisation and accumulation in the mitochondria.[10]

(c). Targeting strategies for mitochondrial localization

Mitochondrial localisation targets are important for improving the selectivity and effectiveness of nanocarrier-based cancer treatment. These strategies are based on molecular motifs and responsive systems to target therapeutic agents specifically to mitochondria in cancer cells. Targeting sequences and peptides of the mitochondria. Short peptides, known as mitochondrial targeting sequences (MTS), are naturally present in proteins and mediate the import of proteins into mitochondria. Such sequences normally consist of positively charged and amphipathic alpha-helical structures that facilitate recognition and translocation across mitochondrial membranes. Nanocarriers or drugs that can be conjugated with synthetic peptides that mimic MTS or other mitochondria-penetrating peptides (MPPs) may be used to increase mitochondrial uptake at the level of membrane permeation via receptor-mediated endocytosis. This method

enhances selective delivery by exploiting the system of protein import into mitochondria, thereby enhancing drug levels in mitochondria and therapeutic effects.[11]

To target the mitochondrion, such systems can be sensitive to mitochondrial microenvironmental information, such as changes in pH or redox gradients (e.g., large glutathione concentrations) or mitochondrial-specific enzyme activity. Externally provided stimuli, such as light, heat, or magnetic fields, can also be used. The triggers cause conformational alterations or cleavage of linkers in the nanocarrier, leading to the selective release of the drug to the mitochondrial point. This accuracy lowers systemic toxicity and increases the therapeutic effect of the system, which concentrates the active agents in the location where they are most liberally required. Combined, these targeting systems, including peptide-based sequences, DLC moieties, and stimuli-responsive release systems, can be used as versatile tools in the design of nanocarriers that are capable of efficient and specific delivery to the mitochondrion in advancing targeted cancer therapy.[12]

3. Mechanisms of Action in Mitochondrial-Targeted Cancer Therapy

(a). Induction of mitochondrial dysfunction

Mitochondrial dysfunction is a crucial pathway utilised in cancer therapies to induce tumour cell death by disrupting required mitochondrial activities. Some of the resolutions include disruption of the mitochondrial membrane potential, electron transport chain (ETC) interference, and generation of reactive oxygen species (ROS). Mitochondrial membrane potential dissipation. Mitochondrial membrane potential (A) (Δ) is vital in the production of ATP and general functions of the mitochondrion. Disturbance to Δpsm destabilises the electrochemical gradient across the inner mitochondrial membrane, which interferes with oxidative phosphorylation and energy generation. This destabilisation may cause the mitochondrial permeability transition pore (mPTP) to open, resulting in the loss of mitochondrial integrity, release of pro-apoptotic proteins such as cytochrome c, and activation of the intrinsic apoptotic pathway. Mitochondria-targeted therapeutic agents (or nanocarriers) are designed to specifically induce the collapse of Δpsm in cancer cells, which induces apoptosis with minimum side effects on normal cells. Impairment of the electron transport chain.[13]

Overproduction of ROS, however, causes oxidative stress, which destroys mitochondrial DNA, mitochondrial proteins, and lipids, resulting in cell death pathways. Therapeutic strategies affecting the overproduction of

ROS within mitochondria bombard the defences of antioxidants in cancer cells, which in turn favours apoptosis or necrosis. The selective accumulation of mitochondria through nanocarriers can be used to deliver agents that cause ROS or disrupt the activities of mitochondria to amplify the production of ROS in tumour cells and improve treatment and overcome resistance. These mechanisms of action, appointed on gene interference of membrane potential, ETC, and as a result of generating ROS, are the foundations of mitochondrial-targeted therapies that cause mitochondrial dysfunction to selectively destroy cancer cells.[14]

(b). Triggering apoptosis in cancer cells

Activation of intrinsic apoptotic pathways. Mitochondrial signals mainly regulate the intrinsic apoptotic pathway, which is important in ensuring cellular homeostasis by eliminating alarming or defective cells. The production of mitochondrial outer membrane permeabilisation (MOMP) triggers the activation of this pathway in cancer therapy, which in turn results in a cascade of events, ultimately leading to programmed cell death. Efforts to treat mitochondria will focus on inducing MOMP to elicit apoptogenic factors that activate caspase to induce apoptosis only in cancerous cells. freely release Pro-apoptotic Factors. Some pro-apoptotic factors are dilated into the cytosol following MOMP and are released from the mitochondrial intermembrane space. Cytochrome c, a major molecule, binds to apoptotic protease activating factor-1 (Apaf-1) to create the apoptosome, which results in the activation of initiator caspase-9 and initiator caspase-3.[15]

Treatment approaches aim to regulate this balance by blocking anti-apoptotic or activating pro-apoptotic members, which enhances mitochondrial outer membrane permeabilisation and apoptosis. In cancer, nanocarriers or cancer-targeted therapeutic drugs engineered to treat the disease may be used to reintroduce apoptotic potential in cancerous cells to improve therapy effectiveness. Collectively, these mechanisms form the foundation of mitochondrial-targeted therapies, which induce apoptosis by activating inherent mechanisms, releasing pro-apoptotic factors, and modulating the dynamics of mitochondrial-based Bcl-2 family proteins to specifically induce apoptosis in cancer cells.[16]

(c). Inhibition of cancer cell proliferation

Mitochondrial- Dependent Signalling Pathway Modulation. Mitochondria control various signalling pathways that mediate cell proliferation, cell survival, and apoptosis, such as reactive oxygen species (ROS), calcium signalling, and mitochondrial metabolites. It is possible to modulate cancer cell stock growth and cancer cell cycle by regulating these

mitochondrial-dependent signalling pathways. For example, cytoskeletal ROS generation can be targeted to redox-sensitive mitochondrial ROS production pathways to stimulate proliferation. Providing shifts in the balance between growth inhibition and cell death is possible by influencing mitochondrial control of apoptotic and survival pathways by modulating signalling proteins.

The strategic approach to inhibiting the growth of cancer cells is through therapies that interfere with these pathways by targeting mitochondria. Combined, these mechanisms, which disrupt energy metabolism, interfere with the replication of mitochondrial DNA, and modulate mitochondrial signalling, offer a holistic strategy for inhibiting cell growth in cancer cells by targeting mitochondria to complement strategies of inducing apoptosis and disrupting mitochondrial dysfunction.[17, 18]

4. Challenges and Emerging Solutions

(a). Nanoparticle stability and biocompatibility

PEGylation, core crosslinking, protective coatings enhance physiological stability; comprehensive toxicity profiling (immunogenicity, hemocompatibility, organ accumulation) guides safe design; biodegradable polymers and biomimetic coatings minimize accumulation.[19]

(b). Targeting accuracy and specificity

High-tech surface modification. The surface engineering of nanocarriers is key to increasing the targeting accuracy and specificity of delivery to cancer cells that contain mitochondria. Polyethylene glycol (PEG)ylation is one of the techniques that enhance circulation time, lowers non-specifically adsorbed proteins, thus minimizing off-target adsorption. In addition to PEGylation, mitochondrial-targeting ligands, such as mitochondria-penetrating peptides (MPPs), mitochondrial targeting sequences (MTS), and delocalised lipophilic cations (DLCs), such as triphenylphosphonium (TPP), can be used to achieve mitochondrial selectivity. Making conjugates with cancer cell-specific ligands (e.g., antibodies, aptamers, or small molecules that bind to overexpressed receptors) further targets the conjugates to malignant cells. The inclusion of stimuli-responsive surface modifications that react to tumour microenvironmental signals (pH, redox gradients) can induce site-selective activation or release of drugs, thus allowing much greater specificity and lowering systemic toxicity. Dual-mode strategies for improved selectivity. Dual targeting can be used to enhance selectivity and therapeutic efficacy with two or more targeting moieties.[20]

(c). Scalability and manufacturing considerations

Producibility in volume production. Reproducibility when scaling up the production of nanocarriers is also important to maintain the reliability of the uniform effect of therapy and safety. The synthesis of nanoparticles further increases the difficulty because of the stringent control required in terms of size, shape, surface chemistry, and payload loading, making batch-to-batch consistency difficult. The process parameters must be strictly controlled, particularly the mixing rates, temperature, solvent ratios, and reaction time, which must be optimised and standardised. Continuous and automated processes can enhance the reproducibility of processes through the reduction of human error and environmental variability. Strong process analytical technologies (PAT) must be integrated to monitor the fundamental characteristics of quality in real-time so that changes can be immediately implemented to guarantee the consistency of products in industrial quantities. Quality control and standardisation problems.[21]

5. Future Perspectives and Translational Potential

(a). Emerging trends in nanocarrier design

Multi- Functional Smart nanoparticles. Smart nanoparticles are a novel technology of nanocarriers designed with numerous coordinated functions applicable in cancer treatment. These systems are multifunctional and combine targeting, imaging, controlled drug release, and therapeutic actions on a single platform. For example, smart nanocarriers can react to a given stimulus of the tumour microenvironment (e.g., pH, redox potential, or enzyme activity) and release their cargo at the site, thereby reducing systemic toxicity. In addition, they can incorporate therapeutic agents with imaging probes and monitor the drug delivery process and treatment response in real time. To improve the accuracy and effectiveness of mitochondrial targeting and general cancer therapy, sophisticated surface modifications and loading into stimuli-responsive materials are used in the design of such nanoparticles. Theranostics approach integration.

Genomic and proteomic developments permit the detection of patient-specific mitochondrial biomarkers, metabolomics, drug sensitivities, and inhibition of ligand, payload, and release selections. Individual nanocarriers can enhance treatment efficacy by adjusting the nanocarrier physicochemical characteristics and targeting approaches to the individual tumour microenvironment and mitochondrial features of each patient. This method improves therapeutic outcomes and minimises side effects, and is

associated with a larger trend toward precision and personalised medicine in cancer treatment.[22]

(b). Advancements in mitochondrial biology and targeting

Protein therapies can be used with greater specificity and efficacy with minimal harm to normal cells with more homogenous mitochondrial functionality by preferentially attacking variants of the mitochondrion that provide protection against survival or resistance to treatment. Targeting mitochondrial metabolism in cancer stem cells. Cancer stem cells (CSCs) constitute a subpopulation of tumours that causes therapy resistance, metastasis, and relapse. These cells have distinctive mitochondrial metabolic phenotypes, which in many cases, place a greater dependence on oxidative phosphorylation than bulk tumour cells.

Mitochondrial Transfer Mitochondrial Transfer as a Therapeutic Strategy. The transfer of mitochondria or mitochondrial fragments between cells, termed mitochondrial transfer, is an intercellular process of the mitochondria that is increasingly being identified in cancer biology. Tumour cells may take over healthy mitochondria of stromal or immune cells to regain their mitochondrial capabilities, which contributes to their survival as well as resistance to therapy. In contrast, therapeutic protocols are being constructed to regulate the transfer of mitochondria to suppress this rescue pathway or provide normal mitochondria to injured cells. Nanotechnology and mitochondrial-targeted delivery systems are under investigation to regulate the transfer of mitochondria or mitochondrial parts into cancer cells to create mitochondrial dysfunction. This new paradigm provides a new perspective on mitochondrial-targeted cancer screening because it involves cellular interactions and mitochondrial dynamics at a broader level, in addition to the cellular level. [23]

Conclusion

(a). Summary of key findings and advancements

The combination of nanotechnology and mitochondrial targeting is a groundbreaking therapeutic method for cancer therapy that overcomes major shortcomings of traditional treatments. Engineered nanocarriers used to deliver drugs to the mitochondrion have taken advantage of physicochemical characteristics, superior targeting ligands, and stimuli-responsive strategies that promote accurate targeting of the cancer cell mitochondrion. This selectivity increases the therapeutic effect by inducing mitochondrial malfunction, stimulating intrinsic mechanisms of cellular apoptosis, and preventing excessive growth of cancer cells by interfering with energy metabolism and mitochondrial signalling. Key

innovations encompass the development of various nanocarrier systems (e.g., liposomes, dendrimers, and polymeric nanoparticles), each with unique benefits in terms of biocompatibility, the ability to handle an unlimited range of drugs, and functionalization capability. [24]

The surface alteration using mitochondrial targeting sequences, delocalised lipophilic cations, and peptides has enhanced mitochondrial accumulation and selectivity. The integrative power of smart nanoparticles to provide theranostic functionalities, which facilitate the combination of treatment and real-time monitoring, has contributed to the development of personalised medicine.

Developments in mitochondrial heterogeneity and metabolism, as observed in cancerous cells, have been used to design nanocarriers that can intercept these findings. New techniques for manipulating mitochondrial transfer further increase treatment options. Advances in nanoparticle stability, biocompatibility, and scalable manufacturing enrich clinical translation opportunities. Considering all the above results together highlights the high potential of nanotechnology applications involving the use of mitochondrial targeting as the key to overcoming resistance, decreasing systemic toxicity, and enhancing the success of cancer treatment. Clinical assessment and regulatory efforts to improve these strategies toward successful targeted mitochondrial-focused cancer continue, and eventually evolve into effective and personalised treatments.[26]

(b). Implications for cancer treatment

Theoretical implications for personalised medicine strategies. Drug delivery through the combination of nanotechnology and mitochondrial targeting has great potential for the development of personalised medicine in cancer treatment. Nanocarriers can be designed to take advantage of patient-specific mitochondrial and tumour phenotypes, such as genetic mutations, metabolic status, and mitochondrial heterogeneity, to facilitate the targeted delivery of therapeutic agents to cancer cells mitochondria.

Such personalisation increases the specificity and effectiveness of the treatment, decreases off-target effects, and increases drug responsiveness. Individualised nanocarriers can adopt the personalised tumour microenvironment and mitochondrial features of an individual patient, including targeting ligands and stimuli release, and theranostic features. In turn, this method facilitates the stratification of patients and real-time changes in the treatment, which coincides with the objectives of precision oncology to achieve a high degree of therapeutic optimisation owing to individual differences.

Future of Enriching Patient Outcomes and Quality of Life. Mitochondrial-targeted nanocarrier-based therapies can positively transform patient outcomes by addressing the shortcomings of existing cancer therapy methods, such as systemic toxicity, drug resistance, and relapse. Extensive targeting precision reduces harm to normal tissues, thereby decreasing adverse side effects and enhancing tolerability. The selective induction of mitochondrial dysfunction in cancer cells facilitates efficient tumour ablation, including those with cancer stem cell populations, thus reducing recurrence rates.[24]

Moreover, diagnostic and therapeutic multifunctional nanocarriers allow the monitoring of treatment response in real-time, facilitating easier clinical decision-making and optimising treatment regimens individually. All these improvements have the potential to make treatment more efficient, less toxic, and increase survival rates and quality of life in cancer patients because of a decrease in treatment-related morbidity and an increase in disease progression control.

(c). Call for multidisciplinary collaboration

The development of mitochondrial-targeted cancer nanocarrier therapies requires the collaboration of experts from various scientific and clinical fields. These complex therapeutic systems can only be developed and implemented effectively with the participation of molecular biologists, nanotechnologists, chemists, pharmacologists, oncologists, and regulatory specialists. Molecular biologists and cancer researchers provide critical information on mitochondrial biology, heterogeneity, and cancer-specific metabolic pathways, which is essential for selecting accurate targets. Nanotechnologists and material scientists design and engineer nanocarries with enhanced physicochemical characteristics, ligand targeting, and stimuli-responsive characteristics.

Toxicologists and pharmacologists test biocompatibility, pharmacokinetics, and safety profiles, which are clinically relevant. By providing crucial insights into patient needs, treatment plans, and clinical trial design, clinicians and oncologists play a critical role. Regulatory professionals ease the journey through complicated approval systems by considering quality control, manufacturing excellence, and safety examinations. Such interdisciplinary synergy can accelerate innovation, increase therapeutic effectiveness, and achieve successful clinical translation. Future research should focus on filling strategic gaps in unanswered questions and technological issues. These involve understanding the that is governed by the mechanisms of mitochondrial heterogeneity in different types of cancer and their effects on treatment outcomes, developing efficient and high-capacity nanocarrier production

schemes with strong quality management, and identifying new cancer-specific mitochondrial markers to enhance control specificity.

In addition, more detailed in vivo studies and more sophisticated preclinical models capable of reproducing the tumour microenvironment and mitochondrial dynamics are required to predict clinical outcomes more accurately. The combination of real-time theranostic observation and adaptive treatment is also a valuable research topic. It is necessary to investigate the long-term safety, immunogenicity, and off-target effects of mitochondrial-targeted nanocarriers to gain approval from regulatory bodies and acceptance from patients. Addressing these challenges through multidisciplinary coordination is crucial to maximise the potential of mitochondrial-targeted nanotechnology in cancer treatment.[25]

References

1. Bardia A, et al. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. *Future Oncol*. 2023;20(8):423–436.
2. Jain KK. Personalised medicine for cancer: from drug development into clinical practice. *Expert Opin Pharmacother*. 2005;6(9):1463–1476.
3. Peng L, Gao Z, Liang Y, et al. Nanoparticle-based drug delivery systems: opportunities and challenges in the treatment of esophageal squamous cell carcinoma (ESCC). *Nanoscale*. 2025;17(14):8270–8288.
4. Venit T, et al. Positive regulation of oxidative phosphorylation by nuclear myosin 1 protects cells from metabolic reprogramming and tumorigenesis in mice. *Nat Commun*. 2023;14(1).
5. Cheng G, et al. Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. *BMC Cancer*. 2013;13(1).
6. Choudhury A, et al. Strategic advances in liposomes technology: translational paradigm in transdermal delivery for skin dermatosis. *J Nanobiotechnol*. 2025;23(1).
7. Sanchez-Aranguren L, Al Tahan MA, Uppal M, et al. Mitochondrial-targeted liposome-based drug delivery - Therapeutic potential and challenges. *J Drug Target*. 2024.
8. Ly PD, Ly KN, Phan HL, et al. Recent advances in surface decoration of nanoparticles in drug delivery. *Front Nanotechnol*. 2024;6.
9. Theivendren P, Pavadai P, Veerachamy S, et al. Surface receptor-targeted protein-based nanocarriers for drug delivery: advances in cancer therapy. *Nanotechnology*. 2025;36(12):122003.

10. Karaman DS, et al. Shape engineering vs organic modification of inorganic nanoparticles as a tool for enhancing cellular internalization. *Nanoscale Res Lett*. 2012;7(1).
11. Battogtokh G, Cho YY, Lee JY, Lee HS, Kang HC. Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment. *Front Pharmacol*. 2018;9.
12. Hao J, et al. Smart Nanoarchitectures for Precision RNA Delivery: Harnessing Endogenous and Exogenous Stimuli in Cancer Treatment. *Theranostics*. 2025;15(15):7747–7778.
13. Smaili SS, Hsu YT, Carvalho ACP, et al. Mitochondria, calcium and pro-apoptotic proteins as mediators in cell death signaling. *Braz J Med Biol Res*. 2003;36(2):183–190.
14. Piconi L, et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. *Diabetes Metab Res*. 2006;22(3):198–203.
15. Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. *Cell Death Differ*. 2017;25(1):46–55.
16. Ngoi NYL, et al. Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer. *Cancers*. 2020;12(3):574.
17. Wang L, et al. Curcumin suppresses gastric tumor cell growth via ROS-mediated DNA polymerase γ depletion disrupting cellular bioenergetics. *J Exp Clin Cancer Res*. 2017;36(1).
18. Zhou H, et al. Advanced nitric oxide-activated calcium overload and zinc ion-amplified oxidative imbalance in ferroptosis/apoptosis. *J Nanobiotechnol*. 2025;23(21).
19. Lipsi K, Pande M. Innovative polymer-based therapeutics targeting inflammation for responsive drug delivery in disease treatment. *Inflammopharmacol*. 2025;33(11).
20. You CQ, et al. Subcellular co-delivery of two different site-oriented payloads based on multistage targeted polymeric nanoparticles for enhanced cancer therapy. *J Mater Chem B*. 2018;6(42):6752–6766.
21. Alkanawati MS, Wurm FR, Thérien-Aubin H, Landfester K. Large-Scale Preparation of Polymer Nanocarriers by High-Pressure Microfluidization. *Macromol Mater Eng*. 2017;303(1).
22. Li M, Zhou S, Zhang Y, Li J, Zhang K. Advancements in Tumor-Targeted Nanoparticles: Design Strategies and Multifunctional Therapeutic Approaches. *Nanomaterials*. 2025;15(16):1262.
23. Du H, Xu T, Yu S, Wu S, Zhang J. Mitochondrial metabolism and cancer therapeutic innovation. *Signal Transduct Target Ther*. 2025;10(1).

24. Roszkowski S, Durczyńska Z, Szablewska S. Targeted nanodelivery systems for personalized cancer therapy. *Rep Pract Oncol Radiother*. 2025;29(6):776–788.

25. Mitra A, Nan A, Line B, Ghandehari H. Nanocarriers for Nuclear Imaging and Radiotherapy of Cancer. *Curr Pharm Des*. 2006;12(36):4729–4749.

26. Zhu J, et al. Harnessing nanotechnology for cancer treatment. *Front Bioeng Biotechnol*. 2025;12.